These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11869573)

  • 21. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
    Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
    Iorio A; Marchesini E; Awad T; Gluud LL
    Cochrane Database Syst Rev; 2010 Jan; (1):CD004888. PubMed ID: 20091566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
    Sun J; Ding H; Chen G; Wang G; Wei L; Zhang J; Xie Q; Wan M; Tang H; Chen S; Gao Z; Wang Y; Zhang D; Huang W; Sheng J; Ning Q; Yang D; Lu J; Pan C; Yang Y; Wang J; Sun C; Wang Q; Hou J
    BMC Gastroenterol; 2019 May; 19(1):65. PubMed ID: 31046700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicinal herbs for hepatitis C virus infection.
    Liu JP; Manheimer E; Tsutani K; Gluud C
    Cochrane Database Syst Rev; 2001; 2001(4):CD003183. PubMed ID: 11687177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
    Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
    J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
    Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
    Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
    Chou R; Carson S; Chan BK
    J Viral Hepat; 2008 Aug; 15(8):551-70. PubMed ID: 18482285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection.
    Xia Y; Luo H; Liu JP; Gluud C
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009004. PubMed ID: 23633363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of interferon in the treatment of acute hepatitis C].
    Simonović-Babić J; Delić D; Svirtlih N
    Med Pregl; 2007; 60(7-8):322-6. PubMed ID: 17990796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.
    Jacobson KR; Murray K; Zellos A; Schwarz KB
    J Pediatr Gastroenterol Nutr; 2002 Jan; 34(1):52-8. PubMed ID: 11753165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
    Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial.
    Fontana RJ; Walsh J; Moyer CA; Lok AS; Webster S; Klein S
    J Clin Gastroenterol; 2002 Feb; 34(2):177-82. PubMed ID: 11782615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.